CJC-1295 and Ipamorelin are both growth hormone-releasing peptides. CJC-1295, identified as a long-acting growth hormone-releasing factor analog, has been shown to significantly boost growth hormone and IGF-1 levels in adults, and restore normal growth in GHRH-deficient mice. Ipamorelin, a ghrelin mimetic, has been studied for its ability to accelerate gastrointestinal recovery after bowel surgery, reducing postoperative ileus and shortening hospital stays. While both peptides impact the growth hormone axis, CJC-1295's primary documented effect in our corpus is sustained growth hormone elevation, whereas Ipamorelin's is related to GI motility and recovery.
| CJC-1295 | Ipamorelin | |
|---|---|---|
| Drug class | ghrh analog | ghrh secretagogue, ghrelin mimetic |
| Studies in corpus | 25 | 45 |
| Highest evidence tier | rct | rct |
| Evidence tier mix | in vitro · 6 preclinical animal · 2 rct · 2 other · 13 review · 1 | other · 12 preclinical animal · 22 rct · 4 in vitro · 5 review · 1 |
| Studies with explicit sample size | 0 | 3 |
| Head-to-head studies in corpus | 1 | |
Beyond the literature: here's what third-party Certificate-of-Analysis records (Janoshik, BCC, Auxlabs) say about real CJC-1295 and Ipamorelin batches we've tested. Aggregate, public data — cross-reference against the studies below.
We tested 746 CJC-1295 batches across 335 manufacturers, 97.33% avg purity.
We tested 1210 Ipamorelin batches across 562 manufacturers, 99.44% avg purity.
We hold deeper lab coverage on Ipamorelin (1210 batches tested). Ipamorelin edges ahead on average measured purity (97.33% vs 99.44%) — a narrow gap; weigh it against failed-batch and underdose counts above.
Studies in our corpus that mention both CJC-1295 and Ipamorelin — the gold-standard direct comparison evidence.
This review highlights a critical distinction for peptide users and clinicians: only GLP-1R agonists currently possess reproducible, high-quality evidence for a specific musculoskeletal indication (knee osteoarthritis symptom relief). For other widely promo…
No direct head-to-head trials in our corpus. Indirect comparison only. CJC-1295 functions as a long-lasting growth hormone-releasing factor analog, with preclinical studies demonstrating its ability to provide sustained elevation of GH levels through albumin bioconjugation. One human RCT showed its efficacy in boosting GH and IGF-1, though another Phase 2 study for HIV-associated visceral obesity was terminated early. Ipamorelin, on the other hand, mimics ghrelin to stimulate growth hormone release and has shown promise in multiple RCTs for accelerating bowel recovery after surgery, reducing postoperative ileus and hospital stays. The evidence for CJC-1295 in our corpus primarily focuses on its growth hormone-stimulating properties and sustained action, while Ipamorelin's evidence highlights its role in improving gastrointestinal motility and post-surgical recovery.
Looking for vendor-level purity, endotoxin, and HPLC data on CJC-1295 or Ipamorelin? TitrateLab tracks Certificate-of-Analysis records from the major peptide labs (Janoshik, BCC, Auxlabs) alongside the research above. Cross-reference vendor batches against the studies on this page.